Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
3.82 | -4.02% | -0.16 |
MRNS closed down 4.02 percent on Thursday, April 18, 2019, on 64 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical MRNS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -4.02% | |
| Down 3 Days in a Row | Weakness | -4.02% | |
| Down 4 Days in a Row | Weakness | -4.02% | |
| Down 5 Days in a Row | Weakness | -4.02% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-12
- Sector: Healthcare
- Industry: Biotechnology
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Chemistry Physical Sciences Drugs Alcohols Ketones Pregnanes Sedatives Neurosteroids
Chemistry Physical Sciences Drugs Alcohols Ketones Pregnanes Sedatives Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRNS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 10.54 |
| 52 Week Low | 2.36 |
| Average Volume | 759,107 |
| 200-Day Moving Average | 5.1925 |
| 50-Day Moving Average | 3.916 |
| 20-Day Moving Average | 4.17 |
| 10-Day Moving Average | 4.275 |
| Average True Range | 0.2701 |
| ADX | 32.24 |
| +DI | 22.3724 |
| -DI | 21.124 |
| Chandelier Exit (Long, 3 ATRs ) | 3.8797 |
| Chandelier Exit (Short, 3 ATRs ) | 4.4503 |
| Upper Bollinger Band | 4.6745 |
| Lower Bollinger Band | 3.6655 |
| Percent B (%b) | 0.15 |
| BandWidth | 24.196643 |
| MACD Line | 0.0518 |
| MACD Signal Line | 0.122 |
| MACD Histogram | -0.0702 |
| Fundamentals | Value |
|---|---|
| Market Cap | 99.61 Million |
| Num Shares | 26.1 Million |
| EPS | -1.10 |
| Price-to-Earnings (P/E) Ratio | -3.47 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 7.28 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.15 | ||||
| Resistance 3 (R3) | 4.17 | 4.08 | 4.10 | ||
| Resistance 2 (R2) | 4.08 | 4.00 | 4.07 | 4.08 | |
| Resistance 1 (R1) | 3.95 | 3.94 | 3.91 | 3.93 | 4.06 |
| Pivot Point | 3.86 | 3.86 | 3.84 | 3.85 | 3.86 |
| Support 1 (S1) | 3.73 | 3.78 | 3.69 | 3.71 | 3.58 |
| Support 2 (S2) | 3.64 | 3.72 | 3.63 | 3.56 | |
| Support 3 (S3) | 3.51 | 3.64 | 3.55 | ||
| Support 4 (S4) | 3.49 |
